文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一项比较两种治疗策略的随机临床试验,评估汉密尔顿抑郁量表(HAM-D)在重度抑郁症患者中的意义。

A Randomized Clinical Trial Comparing Two Treatment Strategies, Evaluating the Meaningfulness of HAM-D Rating Scale in Patients With Major Depressive Disorder.

作者信息

Asghar Junaid, Tabasam Madiha, Althobaiti Maha M, Adnan Ashour Amal, Aleid Mohammed A, Ibrahim Khalaf Osamah, Aldhyani Theyazn H H

机构信息

Faculty of Pharmacy, Gomal University, D. I. Khan, Pakistan.

Department of Computer Science, Taif University, Taif, Saudi Arabia.

出版信息

Front Psychiatry. 2022 May 27;13:873693. doi: 10.3389/fpsyt.2022.873693. eCollection 2022.


DOI:10.3389/fpsyt.2022.873693
PMID:35722557
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9197773/
Abstract

INTRODUCTION: Due to the complexity of symptoms in major depressive disorder (MDD), the majority of depression scales fall short of accurately assessing a patient's progress. When selecting the most appropriate antidepressant treatment in MDD, a multidimensional scale such as the Hamilton Depression Rating scale (HAM-D) may provide clinicians with more information especially when coupled with unidimensional analysis of some key factors such as depressed mood, altered sleep, psychic and somatic anxiety and suicidal ideation etc. METHODS: HAM-D measurements were carried out in patients with MDD when treated with two different therapeutic interventions. The prespecified primary efficacy variables for the study were changes in score from baseline to the end of the 12 weeks on HAM-D scale (i.e., ≤ 8 or ≥50% response). The study involved three assessment points (baseline, 6 weeks and 12 weeks). RESULTS: Evaluation of both the absolute HAM-D scores and four factors derived from the HAM-D (depressed mood, sleep, psychic and somatic anxiety and suicidal ideation) revealed that the latter showed a greater promise in gauging the anti-depressant responses. CONCLUSION: The study confirms the assumption that while both drugs may improve several items on the HAM-D scale, the overall protocol may fall short of addressing the symptoms diversity in MDD and thus the analysis of factor (s) in question might be more relevant and meaningful.

摘要

引言:由于重度抑郁症(MDD)症状的复杂性,大多数抑郁量表都无法准确评估患者的进展。在为MDD患者选择最合适的抗抑郁治疗方法时,像汉密尔顿抑郁量表(HAM-D)这样的多维量表可能会为临床医生提供更多信息,特别是当结合对一些关键因素(如情绪低落、睡眠改变、精神和躯体焦虑以及自杀观念等)进行单维分析时。 方法:对接受两种不同治疗干预的MDD患者进行HAM-D测量。该研究预先设定的主要疗效变量是从基线到12周结束时HAM-D量表评分的变化(即,≤8或≥50%的反应)。该研究涉及三个评估点(基线、6周和12周)。 结果:对绝对HAM-D评分以及从HAM-D得出的四个因素(情绪低落、睡眠、精神和躯体焦虑以及自杀观念)的评估表明,后者在衡量抗抑郁反应方面显示出更大的前景。 结论:该研究证实了这样一种假设,即虽然两种药物都可能改善HAM-D量表上的几个项目,但总体方案可能无法解决MDD症状的多样性问题,因此对相关因素的分析可能更具相关性和意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/69cb89a83aea/fpsyt-13-873693-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/e39c83009bd2/fpsyt-13-873693-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/0a6849fadd9a/fpsyt-13-873693-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/9156eb69c32c/fpsyt-13-873693-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/efd52c8e5db7/fpsyt-13-873693-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/60aebfa94454/fpsyt-13-873693-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/4b171e54d207/fpsyt-13-873693-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/6e0301fc3766/fpsyt-13-873693-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/69cb89a83aea/fpsyt-13-873693-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/e39c83009bd2/fpsyt-13-873693-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/0a6849fadd9a/fpsyt-13-873693-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/9156eb69c32c/fpsyt-13-873693-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/efd52c8e5db7/fpsyt-13-873693-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/60aebfa94454/fpsyt-13-873693-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/4b171e54d207/fpsyt-13-873693-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/6e0301fc3766/fpsyt-13-873693-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36d5/9197773/69cb89a83aea/fpsyt-13-873693-g0008.jpg

相似文献

[1]
A Randomized Clinical Trial Comparing Two Treatment Strategies, Evaluating the Meaningfulness of HAM-D Rating Scale in Patients With Major Depressive Disorder.

Front Psychiatry. 2022-5-27

[2]
Novel Augmentation Strategies in Major Depression.

Dan Med J. 2017-4

[3]
Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.

J Clin Psychiatry. 2004-8

[4]
Escitalopram in the treatment of anxiety symptoms associated with depression.

Depress Anxiety. 2007

[5]
Assessment of the psychometric properties of the 17- and 6-item Hamilton Depression Rating Scales in major depressive disorder, bipolar depression and bipolar depression with mixed features.

J Psychiatr Res. 2018-7-21

[6]
Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.

Psychopharmacol Bull. 2007

[7]
Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.

J Clin Psychiatry. 2006-3

[8]
Fluoxetine treatment of depressed patients with comorbid anxiety disorders.

J Psychopharmacol. 2002-9

[9]
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

JAMA. 2000-6-21

[10]
Efficacy of vortioxetine on the physical symptoms of major depressive disorder.

J Psychopharmacol. 2018-7-26

引用本文的文献

[1]
Impute the missing data by combining retrieved dropouts and return to baseline method.

PLoS One. 2025-5-29

[2]
Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder: The UNITE Randomized Clinical Trial.

JAMA Neurol. 2025-5-5

[3]
Development of Composite Index in Psychiatry Clinical Trial.

Ther Innov Regul Sci. 2025-4-7

[4]
Data-centric automated approach to predict autism spectrum disorder based on selective features and explainable artificial intelligence.

Front Comput Neurosci. 2024-10-21

[5]
An Evaluation of the Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Management of Treatment-Resistant Depression with Somatic Attributes: A Hospital-Based Study in Oman.

Brain Sci. 2023-9-6

本文引用的文献

[1]
Time for united action on depression: a Lancet-World Psychiatric Association Commission.

Lancet. 2022-3-5

[2]
Optimizing personalized management of depression: the importance of real-world contexts and the need for a new convergence paradigm in mental health.

World Psychiatry. 2020-10

[3]
The clinical characterization of the adult patient with depression aimed at personalization of management.

World Psychiatry. 2020-10

[4]
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.

J Affect Disord. 2019-3-6

[5]
Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?

Handb Exp Pharmacol. 2019

[6]
Risk Factors for Recent Suicide Attempts in Major Depressive Disorder Patients in China: Results From a National Study.

Front Psychiatry. 2018-7-3

[7]
Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project.

Int J Neuropsychopharmacol. 2018-9-1

[8]
[Association between adverse childhood experiences with depression in adults consulting in primary care].

Rev Med Chil. 2017-9

[9]
Effects of Antidepressants on Sleep.

Curr Psychiatry Rep. 2017-8-9

[10]
Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.

JAMA Psychiatry. 2017-4-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索